Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	10	-	36.46	-
Cost of Revenue	-	2.57	-1.15	17.91	-
Gross Profit	-	7.43	1.15	18.56	-
Selling, General & Admin	26.43	18.42	26.11	15.93	21.22
Research & Development	19.28	16.14	27.74	23.56	16.35
Operating Expenses	45.72	34.56	53.84	39.49	37.57
Operating Income	-45.72	-27.14	-52.7	-20.94	-37.57
Interest Expense	-1.37	-2.88	-4.18	-3.78	-6.23
Interest & Investment Income	3.04	2.13	0.84	0	0.01
Currency Exchange Gain (Loss)	1.21	-2.35	2.72	-0.95	-1.82
Other Non Operating Income (Expenses)	-0.42	0.24	10.37	39.79	-110.01
EBT Excluding Unusual Items	-43.25	-30	-42.94	14.13	-155.62
Gain (Loss) on Sale of Investments	-	-	-	-	0.04
Gain (Loss) on Sale of Assets	-	-	-	0.11	-10.87
Pretax Income	-43.25	-30	-42.94	14.24	-166.45
Income Tax Expense	-	-0.53	-0.72	1.52	-2.82
Net Income	-43.25	-29.47	-42.22	12.73	-163.63
Net Income to Common	-43.25	-29.47	-42.22	12.73	-163.63
Shares Outstanding (Basic)	148	132	121	106	68
Shares Outstanding (Diluted)	148	132	121	111	68
Shares Change (YoY)	12.16%	9.33%	8.63%	63.82%	279.04%
EPS (Basic)	-0.29	-0.22	-0.35	0.12	-2.41
EPS (Diluted)	-0.29	-0.22	-0.35	-0.23	-2.41
Free Cash Flow	-32.83	-21.13	-48.83	-5.77	-28.36
Free Cash Flow Per Share	-0.22	-0.16	-0.41	-0.05	-0.42
Gross Margin	-	74.26%	-	50.89%	-
Operating Margin	-	-271.36%	-	-57.42%	-
Profit Margin	-	-294.66%	-	34.90%	-
Free Cash Flow Margin	-	-211.32%	-	-15.83%	-
EBITDA	-45.13	-26.57	-52.52	-20.86	-35.97
EBITDA Margin	-	-265.70%	-	-57.22%	-
D&A For EBITDA	0.58	0.57	0.18	0.07	1.6
EBIT	-45.72	-27.14	-52.7	-20.94	-37.57
EBIT Margin	-	-271.36%	-	-57.42%	-
Effective Tax Rate	-	-	-	10.64%	-

Updated Mar 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q